Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2018 Jun 18;27(7):1111–1125. doi: 10.1177/0963689718773333

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s) 2018

This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 License (http://www.creativecommons.org/licenses/by-nc/4.0/) which permits non-commercial use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access pages (https://us.sagepub.com/en-us/nam/open-access-at-sage).

PMC Copyright notice

Fig. 5. — Type X collagen expression exhibited cartilage quality of autologous ASC+HA and SVF+HA treatments. (A) Immunohistochemistry results showed that hypertrophic chondrocytes expressing collagen X were in alignment at the deep of articular cartilage in the non-injured group. Few collagen-X-positive chondrocytes were observed in the saline and HA-treated groups while high-dose ASC+HA treatment rescued hypertrophic chondrocytes expressing collagen X at the deep area of articular cartilage. It seemed that low-dose ASC+HA treatment showed more collagen-X-positive hypertrophic chondrocytes than that of in SVF+HA treatment. (B, C) Western blot and densitometry analysis results also showed that high- and low-dose ASC+HA treatments expressed collagen X while SVF+HA treatment showed weak expression.